Flavivirus Entry Inhibitors

Qing Yin Wang, Pei-Yong Shi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Many flaviviruses are significant human pathogens that are transmitted by mosquitoes and ticks. Although effective vaccines are available for yellow fever virus, Japanese encephalitic virus, and tick-borne encephalitis virus, these and other flaviviruses still cause thousands of human deaths and millions of illnesses each year. No clinically approved antiviral therapy is available for flavivirus treatment. To meet this unmet medical need, industry and academia have taken multiple approaches to develop antiflavivirus therapy, among which targeting viral entry has been actively pursued in the past decade. Here we review the current knowledge of flavivirus entry and its use for small molecule drug discovery. Inhibitors of two major steps of flaviviral entry have been reported: (i) molecules that block virus-receptor interaction; (ii) compounds that prevent conformational change of viral envelope protein during virus-host membrane fusion. We also discuss the advantages and disadvantages of targeting viral entry for treatment of flavivirus infection as compared to targeting viral replication proteins.

Original languageEnglish (US)
Pages (from-to)428-434
Number of pages7
JournalACS Infectious Diseases
Volume1
Issue number9
DOIs
StatePublished - Jan 8 2016
Externally publishedYes

Fingerprint

Flavivirus
Flavivirus Infections
Yellow fever virus
Viral Envelope Proteins
Tick-Borne Encephalitis Viruses
Virus Receptors
Virus Internalization
Viral Proteins
Ticks
Drug Discovery
Culicidae
Antiviral Agents
Industry
Vaccines
Viruses
Therapeutics

Keywords

  • antivirals
  • flavivirus
  • virus entry

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Flavivirus Entry Inhibitors. / Wang, Qing Yin; Shi, Pei-Yong.

In: ACS Infectious Diseases, Vol. 1, No. 9, 08.01.2016, p. 428-434.

Research output: Contribution to journalArticle

Wang, Qing Yin ; Shi, Pei-Yong. / Flavivirus Entry Inhibitors. In: ACS Infectious Diseases. 2016 ; Vol. 1, No. 9. pp. 428-434.
@article{7df70481d5e240fe8a6fa6bd4306f94c,
title = "Flavivirus Entry Inhibitors",
abstract = "Many flaviviruses are significant human pathogens that are transmitted by mosquitoes and ticks. Although effective vaccines are available for yellow fever virus, Japanese encephalitic virus, and tick-borne encephalitis virus, these and other flaviviruses still cause thousands of human deaths and millions of illnesses each year. No clinically approved antiviral therapy is available for flavivirus treatment. To meet this unmet medical need, industry and academia have taken multiple approaches to develop antiflavivirus therapy, among which targeting viral entry has been actively pursued in the past decade. Here we review the current knowledge of flavivirus entry and its use for small molecule drug discovery. Inhibitors of two major steps of flaviviral entry have been reported: (i) molecules that block virus-receptor interaction; (ii) compounds that prevent conformational change of viral envelope protein during virus-host membrane fusion. We also discuss the advantages and disadvantages of targeting viral entry for treatment of flavivirus infection as compared to targeting viral replication proteins.",
keywords = "antivirals, flavivirus, virus entry",
author = "Wang, {Qing Yin} and Pei-Yong Shi",
year = "2016",
month = "1",
day = "8",
doi = "10.1021/acsinfecdis.5b00066",
language = "English (US)",
volume = "1",
pages = "428--434",
journal = "ACS Infectious Diseases",
issn = "2373-8227",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Flavivirus Entry Inhibitors

AU - Wang, Qing Yin

AU - Shi, Pei-Yong

PY - 2016/1/8

Y1 - 2016/1/8

N2 - Many flaviviruses are significant human pathogens that are transmitted by mosquitoes and ticks. Although effective vaccines are available for yellow fever virus, Japanese encephalitic virus, and tick-borne encephalitis virus, these and other flaviviruses still cause thousands of human deaths and millions of illnesses each year. No clinically approved antiviral therapy is available for flavivirus treatment. To meet this unmet medical need, industry and academia have taken multiple approaches to develop antiflavivirus therapy, among which targeting viral entry has been actively pursued in the past decade. Here we review the current knowledge of flavivirus entry and its use for small molecule drug discovery. Inhibitors of two major steps of flaviviral entry have been reported: (i) molecules that block virus-receptor interaction; (ii) compounds that prevent conformational change of viral envelope protein during virus-host membrane fusion. We also discuss the advantages and disadvantages of targeting viral entry for treatment of flavivirus infection as compared to targeting viral replication proteins.

AB - Many flaviviruses are significant human pathogens that are transmitted by mosquitoes and ticks. Although effective vaccines are available for yellow fever virus, Japanese encephalitic virus, and tick-borne encephalitis virus, these and other flaviviruses still cause thousands of human deaths and millions of illnesses each year. No clinically approved antiviral therapy is available for flavivirus treatment. To meet this unmet medical need, industry and academia have taken multiple approaches to develop antiflavivirus therapy, among which targeting viral entry has been actively pursued in the past decade. Here we review the current knowledge of flavivirus entry and its use for small molecule drug discovery. Inhibitors of two major steps of flaviviral entry have been reported: (i) molecules that block virus-receptor interaction; (ii) compounds that prevent conformational change of viral envelope protein during virus-host membrane fusion. We also discuss the advantages and disadvantages of targeting viral entry for treatment of flavivirus infection as compared to targeting viral replication proteins.

KW - antivirals

KW - flavivirus

KW - virus entry

UR - http://www.scopus.com/inward/record.url?scp=84969211386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969211386&partnerID=8YFLogxK

U2 - 10.1021/acsinfecdis.5b00066

DO - 10.1021/acsinfecdis.5b00066

M3 - Article

VL - 1

SP - 428

EP - 434

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

SN - 2373-8227

IS - 9

ER -